Drug Information

Drug General Information
Drug ID
D08AWN
Former ID
DNC008743
Drug Name
(S)-Norfluoxetine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529814]
Structure
Download
2D MOL

3D MOL
Formula
C16H16F3NO
Canonical SMILES
C1=CC=C(C=C1)C(CCN)OC2=CC=C(C=C2)C(F)(F)F
InChI
1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m0/s1
InChIKey
WIQRCHMSJFFONW-HNNXBMFYSA-N
CAS Number
CAS 126924-38-7
PubChem Compound ID
3058751
Target and Pathway
Target(s) Sodium-dependent noradrenaline transporter Target Info Inhibitor [529814]
Sodium-dependent serotonin transporter Target Info Inhibitor [529814]
Sodium-dependent dopamine transporter Target Info Inhibitor [529814]
KEGG Pathway Serotonergic synapsehsa04728:Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Amphetamine addiction
Alcoholism
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
Parkinson disease
Dopamine receptor mediated signaling pathway
Pathway Interaction Database Alpha-synuclein signaling
Reactome Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
WikiPathways Monoamine Transport
NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
SIDS Susceptibility Pathways
Synaptic Vesicle Pathway
Serotonin Transporter ActivityWP727:Monoamine Transport
Dopaminergic Neurogenesis
Parkinsons Disease Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Neurotransmitter Clearance In The Synaptic Cleft
References
Ref 529814Bioorg Med Chem. 2009 Jan 1;17(1):337-43. Epub 2008 Nov 5.Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
Ref 529814Bioorg Med Chem. 2009 Jan 1;17(1):337-43. Epub 2008 Nov 5.Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.